Amarin Corp. Plc, a biopharmaceutical company, specializes in developing and commercializing therapeutics aimed at enhancing cardiovascular health, primarily through its lead product, Vascepa. Vascepa, used to lower triglyceride levels in adults with severe hypertriglyceridemia, is distributed mainly to wholesalers and pharmacies.
Amarin Corp (AMRN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Amarin Corp's actual EPS was $0.01, beating the estimate of -$0.04 per share, resulting in a 126.11% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
